Related Experiment Video

Updated: Jun 17, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Diagnostic challenges and recent advances in the early management of invasive fungal infections

Pranatharthi Chandrasekar1

  • 1Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI 48201, USA. pchandrasekar@med.wayne.edu

European Journal of Haematology
|December 17, 2009
PubMed

Insights

Diagnosing invasive fungal infections (IFIs) early is crucial. New non-invasive methods offer faster, more accurate detection in immunocompromised patients, improving treatment outcomes and reducing mortality.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Clinical Diagnostics

Background:

  • Increasing population of immunocompromised patients at risk for invasive fungal infections (IFIs).
  • Shift in fungal epidemiology towards non-Aspergillus molds and yeasts, often with antifungal drug resistance.
  • Limitations of traditional diagnostic methods (culture, histopathology) in early and accurate IFI detection.

Purpose of the Study:

  • Review current diagnostic and treatment approaches for invasive fungal infections.
  • Highlight the importance of early and accurate diagnosis in guiding treatment and improving patient outcomes.
  • Discuss strategies for enhancing the management of IFIs.

Main Methods:

  • Review of current literature on invasive fungal infections diagnosis and treatment.
  • Focus on advancements in non-invasive diagnostic techniques.
  • Analysis of how early diagnosis impacts treatment efficacy.

Main Results:

  • Traditional methods often delay IFI diagnosis.
  • Invasive diagnostic procedures can be contraindicated in critically ill patients.
  • Emerging non-invasive techniques (serum markers, PCR assays) show promise for earlier and more accurate diagnosis.

Conclusions:

  • Early and accurate diagnosis of IFIs is critical for reducing morbidity and mortality.
  • Non-invasive diagnostic tools are essential for timely management of IFIs in at-risk populations.
  • Improved diagnostic strategies can significantly enhance patient outcomes in IFIs.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).